Literature DB >> 1834010

Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin.

E M Bailey1, M J Rybak, G W Kaatz.   

Abstract

The effect of protein binding on the activity of teicoplanin against Staphylococcus aureus was evaluated. Bactericidal rates of teicoplanin in cation-supplemented Mueller-Hinton broth (SMHB) and in a 1:1 mixture of pooled human serum and cation-supplemented Mueller-Hinton broth (PHS-SMHB) were compared with those of vancomycin. Eight concentrations of each drug ranging from 15 to 150 micrograms/ml were studied in two series which correspond to the concentrations in serum achieved with low- (6 mg/kg of body weight once daily) and high-dose (30 mg/kg once daily) teicoplanin. Overall, the bactericidal rate of teicoplanin was lower than that of vancomycin. In the presence of serum, the bactericidal rate of teicoplanin in PHS-SMHB was lower than that in SMHB, often resulting in only one log10 drop in CFU over a 24-h period. There was no statistical difference in the bactericidal rates of high- and low-concentration teicoplanin in either medium. Additionally, concentration-dependent killing in SMHB was not evident with either agent. The bactericidal rates of teicoplanin and vancomycin in a 1:1 mixture of serum ultrafiltrate and SMHB at 60 micrograms/ml were also studied. It was noted that the bactericidal rate of neither agent was affected by the presence of serum ultrafiltrate. This finding is consistent with teicoplanin's high degree of protein binding (reported to be greater than 90% in undiluted serum) and further substantiates the hypothesis that only the free drug is active against microorganisms. These data support protein binding as being a factor in teicoplanin activity against S. aureus.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1834010      PMCID: PMC284292          DOI: 10.1128/AAC.35.6.1089

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis.

Authors:  H F Chambers; S Kennedy
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

Review 2.  The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy.

Authors:  R Wise
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

Review 3.  Role of pharmacokinetics in the outcome of infections.

Authors:  G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

4.  Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers.

Authors:  Y W Lam; M H Duroux; J G Gambertoglio; S L Barriere; B J Guglielmo
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

Review 5.  Glycopeptide antibiotics.

Authors:  F Parenti
Journal:  J Clin Pharmacol       Date:  1988-02       Impact factor: 3.126

6.  Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; N J Dorman; S A Lerner
Journal:  J Infect Dis       Date:  1990-07       Impact factor: 5.226

7.  Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography.

Authors:  A C Cremieux; B Maziere; J M Vallois; M Ottaviani; A Azancot; H Raffoul; A Bouvet; J J Pocidalo; C Carbon
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

8.  A sensitive bioassay for teicoplanin in serum in the presence or absence of other antibiotics.

Authors:  R C Erickson; A R Hildebrand; P F Hoffman; C B Gibson
Journal:  Diagn Microbiol Infect Dis       Date:  1989 May-Jun       Impact factor: 2.803

9.  Comparison of pharmacokinetics and bactericidal activity of teicoplanin and vancomycin.

Authors:  H Lagast; P Dodion; J Klastersky
Journal:  J Antimicrob Chemother       Date:  1986-10       Impact factor: 5.790

10.  Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria.

Authors:  Y Glupczynski; H Lagast; P Van der Auwera; J P Thys; F Crokaert; E Yourassowsky; F Meunier-Carpentier; J Klastersky; J P Kains; E Serruys-Schoutens
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

View more
  36 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Randomized comparison of serum teicoplanin concentrations following daily or alternate daily dosing in healthy adults.

Authors:  Bernard Rouveix; François Jehl; Henri Drugeon; Ivan Brumpt; Evelyne Caulin
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

3.  Effect of ertapenem protein binding on killing of bacteria.

Authors:  David E Nix; Kathryn R Matthias; Emily C Ferguson
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

4.  Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus.

Authors:  G G Zhanel; I D Kirkpatrick; D J Hoban; A M Kabani; J A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

5.  Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model.

Authors:  J D Knudsen; K Fuursted; F Espersen; N Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

6.  Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients.

Authors:  Yasuhiro Tsuji; Nicholas H G Holford; Hidefumi Kasai; Chika Ogami; Young-A Heo; Yoshitsugu Higashi; Akiko Mizoguchi; Hideto To; Yoshihiro Yamamoto
Journal:  Br J Clin Pharmacol       Date:  2017-03-31       Impact factor: 4.335

7.  Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.

Authors:  Jill M Butterfield; Nimish Patel; Manjunath P Pai; Thomas G Rosano; George L Drusano; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

8.  Surface-stress sensors for rapid and ultrasensitive detection of active free drugs in human serum.

Authors:  Joseph W Ndieyira; Natascha Kappeler; Stephen Logan; Matthew A Cooper; Chris Abell; Rachel A McKendry; Gabriel Aeppli
Journal:  Nat Nanotechnol       Date:  2014-03-02       Impact factor: 39.213

9.  Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.

Authors:  R C Mercier; H H Houlihan; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

10.  In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.

Authors:  K C Lamp; M J Rybak; E M Bailey; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.